The AdventHealth Neuroscience Institute will lead first-of-its-kind research on exercise and brain health as part of a national, multisite effort funded with $11 million from the National Institutes of Health (NIH), the largest source of medical research funding worldwide.
Known as Follow-up Longitudinal Analysis of Moderate-intensity Exercise (FLAME), this new effort will test the long-term effects of a previously conducted randomized exercise clinical trial initiated in 2016 called “Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE),” which examined the effects of exercise on cognitive and brain health in cognitively normal older adults.
For the first time, FLAME will examine whether participating in a moderate-intensity exercise intervention influences the rate of cognitive performance changes and risk for Alzheimer’s disease pathology five years later. The FLAME study will also examine the extent to which participants maintained the exercise routines they started in the IGNITE study and determine whether there are any factors predicting long-term adherence to exercise behaviors. In short, the study could help establish evidence for long-term engagement in physical exercise as a leading approach to reducing the risk of age-related cognitive decline and dementia.
“With the number of new Alzheimer’s disease cases expected to grow exponentially, we are interested in how we can continue to capitalize on and leverage the natural properties of the brain to maintain and improve brain function,” said lead researcher Kirk Erickson, Ph.D., director of Translational Neuroscience at the AdventHealth Neuroscience Institute. “While many believe that our brain simply deteriorates, atrophies, and declines inevitably, we are finding that there are things we can do about it and that the brain retains its capacity for modification, even late into life.”
In combination with the results from IGNITE, the results of FLAME are expected to be transformative. Also funded by NIH, the IGNITE randomized clinical trial tested a diverse sample of 648 adults, ages 65–80. The FLAME study will commence with recontacting IGNITE participants in early 2024. The goal of the study will be to reexamine brain function and reevaluate cognition as well as recharacterize aspects of exercise behaviors, health, and physical function among participants.
“This is the first time we are able to take a large, randomized clinical trial of aerobic exercise along with the rich data we gained through IGNITE to examine whether physical activity altered the trajectory of accumulated Alzheimer’s disease pathology,” added Erickson, who is also a professor of psychology at the University of Pittsburgh. “And while we know that exercise, overall, is good for us, this study may prove groundbreaking by not only expanding our understanding of how exercise affects the brain and Alzheimer’s disease but also how we motivate our patients and community to maintain a physically active lifestyle that can help reduce their risk of developing Alzheimer’s disease later in life.”
AdventHealth, the University of Pittsburgh, Northeastern University, and the University of Kansas Medical Center will serve as the sites for this NIH-funded research. In addition to Erickson, study investigators include doctors Jeffery Burns, Eric Vidoni, Chaeryon Kang, Anna Marsland, Dan Forman, Thomas Karikari, Arthur Kramer, Charles Hillman, and Edward McAuley.
The original version of this story was posted on the North American Division website.